We are international
Donate
• about myeloma TEXT SIZE   
publications    back

Myeloma Minute
June 28, 2012
06.28.12
June 28, 2012
Share the Minute Facebook Tweet! Clinical Trials Donate to the IMF
 


Upcoming Events



Reserve Your Tickets Now!


Tickets are now on sale for the IMF’s 6th Annual Comedy Celebration being held on October 27 in Los Angeles. Make plans to join us for the laughs and fun! LEARN MORE




No-Sweat Summer Fundraisers That Can Make a Difference

Get involved, have fun and make a difference this summer by helping fund myeloma research, education and programs! IMF Director of Member Events Suzanne Battaglia offers some out-of-the-box ideas for good works that are good fun. Bet you hadn’t thought of having a “Dress Up” day at the office. Now, where’d we put our tiara??? READ MORE

 

Supreme Court Upholds Affordable Care Act

After months of deliberation, the Supreme Court announced this morning that the Affordable Care Act will remain intact and upheld completely. In a 5-4 decision, Chief Justice John Roberts authored an opinion, which was joined by Justices Breyer, Kagan, Sotomayor and Ginsburg, that upheld the constitutionality of the individual mandate because it is a tax. The Court further decided that the Medicaid expansion is constitutional, but that the federal government cannot withhold existing Medicaid funding for states as punishment for states that do not comply with the expansion requirement.

During the two-year debate on healthcare reform, the IMF fought hard on behalf of myeloma patients for specific reforms which were critical to accessing quality care for ALL cancer patients, including:

  • The elimination of discrimination based on pre –existing conditions
  • The elimination of annual and lifetime insurance caps
  • Closing of the Medicare doughnut hole
  • Access to affordable health insurance
These key issues were all addressed in the Affordable Care Act. At this time, the IMF will remain focused on the implementation of these reforms to ensure access to care for patients facing a cancer diagnosis.

MORE FROM THE IM
F | READ MORE

 

Making Sense of ASCO: Our Summaries of Myeloma Abstracts from the ASCO 2012 Annual Meeting
Following the International Myeloma Foundation’s 10 STEPS TO BETTER CARE™ framework, we’ve summarized the nearly 66 multiple myeloma presentations from the American Society of Clinical Oncology (ASCO) annual meeting June 2-5 in Chicago. Many focused on therapy options for those with refractory and/or relapsed multiple myeloma, with encouraging data on the use of antibodies and proteasome inhibitors in that setting. READ MORE
An Insider’s Look at Last Week’s Carfilzomib Hearing
Dr. Jim Omel played an important role at last week’s FDA hearing on carfilzomib, serving as the myeloma patient representative on the Oncologic Drugs Advisory Committee (ODAC), which voted 11-0 in favor of recommending carfilzomib for approval by the FDA. In his insider’s blog post, Dr. Omel commends the hearing’s patient and IMF representative speakers: “Discussion around the table had a decidedly different tone after the 9 powerful public speakers, and I had great hope for a vote of approval.” READ MORE
Saving a Life, Receiving a Gift: IMF’s Kelly Cox on Being a Bone Marrow Donor
IMF staffer Kelly Cox shares his experience as an anonymous bone marrow donor, which has given him first-hand empathy and admiration for myeloma patients who undergo transplantation as part of their cancer therapy. He writes, “Emotionally, spiritually, and intellectually I am absolutely blown away by the experience. And I am still struggling to wrap my mind around the concept of possibly saving a life.” READ MORE
“Survivorship” Tips from the IMF’s Nurse Leadership Board
The IMF’s Nurse Leadership Board shared a presentation of its visionary “Survivorship Plans” with oncology nurses from across the country last month at a symposium at the Oncology Nursing Society’s 37th Annual Congress in New Orleans, chaired by Dr. Joseph Tariman, a member of the Nurse Leadership Board. These visionary plans are designed to help patients optimize their health and improve their quality of life. Now we are pleased to share the survivorship plans presented at the congress with the entire myeloma community on the IMF website. READ MORE
 
Join Our Mailing List  
 

 

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
Privacy Policy | Unsubscribe 
www.myeloma.org

 related videos
 related articles
#AskDrDurie: My Mai...
#AskDrDurie: Can Mye...
10 PASSI PER CURA MI...
10 Steps to Better C...
10 Steps to Happy Ho...
2011 IMF Holiday Gif...
New Study: The Searc...
Comprender El Tratam...
...
ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - Ap...
Advocacy Update - Ma...
Advocacy Update - Oc...
Advocacy Update - Se...
Advocacy Update: The...
As the Bill Turns......
ASCO 2012: Dr. Pasho...
ASCO 2013: Dr. Jakub...
ASCO 2013: Dr. Lonia...
ASCO 2013: Dr. Pande...
ASCO 2013: Dr. Usman...
ASCO 2013: Dr. Weise...
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken An...
Audio Recording of C...
August 2013 Advocate...
Breaking News: Pomal...
FDA Recognition of E...
Health Reform and Yo...
IMF 6th Annual Comed...
IMF Board Member Edi...
IMF Nurse Leadership...
IMF Responds to Prop...
It is Officially Mye...
jc test
Live from ASH 2012: ...
Live! The Boca Raton...
Living Well with Mye...
Myelom Merkur - Früh...
MYELOMA AWARENESS MO...
Myeloma Canada Annou...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Apri...
Myeloma Minute Febr...
Myeloma Minute Janu...
Myeloma Minute July...
Myeloma Minute Marc...
Myeloma Minute May ...
Myeloma Minute Nove...
Myeloma Minute Octo...
Myeloma Minute Octo...
Myeloma MinuteJune 1...
Myeloma MinuteMay 24...
Myeloma Today Spring...
New! Free Teleconfer...
Patienten Handbuch
Pomalidomide + carfi...
Should Myeloma Patie...
Special Myeloma Minu...
STEP 7: CONSOLIDATIO...
STEP 8: KEEPING TRAC...
Stillwater, Minn., M...
Teleconference: Myel...
The Emerging Role of...
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads N...
The Importance of Cl...
The International My...
The International My...
The International My...
View the IMF’s Multi...
Webcast from the 201...
Клиническое значение...

ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
#AskDrDurie: My Maintenance was Stopped Because the Side Effects were Too Bad. How Common is That?
#AskDrDurie: Can Myeloma Run In The Family?
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care®
10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique

New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage

Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre



Third in the popular series of debates that debuted in Amsterdam in 2012.

Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific

ABOUT BSRI™
ABOUT BSRI®
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - October 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
ASH 2013: Dr. Ken Anderson's Overview
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
August 2013 Advocate of the Month: Judy Lewis
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
IMF 6th Annual Comedy Celebration
benefiting the Peter Boyle Research Fund
October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
April 26, 2012
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 24, 2013
Myeloma Minute
October 25, 2012
Myeloma Minute
June 13, 2013
Myeloma Minute
May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Patienten Handbuch
Pomalidomide + carfilzomib trial recruiting patients.
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie
September 8,2011
The International Myeloma Foundation announces partnership with Onyx Pharmaceuticals to support Black Swan Research Initiative®
The International Myeloma Foundation Reports Live from the 2013 ASH Meeting in New Orleans
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
View the IMF’s Multiple Myeloma Journalists’ Workshop and Webcast from ASH 2013 in New Orleans
Webcast from the 2014 Boca Raton Patient & Family Seminar
February 28 - March 1, 2014

Клиническое значение электрофореза белковых фракций